{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:33:03Z","timestamp":1787020383688,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Chronic myeloid leukaemia (CML) is one of the most well characterised human malignancies. Most patients have a cytogenetically visible translocation between chromosomes 9 and 22 which generates the pathognomonic\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion gene. The derivative chromosome 22 (\u2018Philadelphia\u2019 or Ph chromosome) usually harbours the fusion gene encoding a constitutively active\n                      <jats:italic>ABL1<\/jats:italic>\n                      kinase domain.\n                    <\/jats:p>\n                    <jats:p>\n                      A small subset of patients have no visible translocation. Historically, these \u2018Philadelphia chromosome negative\u2019 patients caused diagnostic confusion between CML and other myeloproliferative neoplasms; it is now well established that the\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion gene can be generated via submicroscopic intrachromosomal insertion of\n                      <jats:italic>ABL1<\/jats:italic>\n                      sequence into\n                      <jats:italic>BCR<\/jats:italic>\n                      , or, more rarely, of\n                      <jats:italic>BCR<\/jats:italic>\n                      into\n                      <jats:italic>ABL1<\/jats:italic>\n                      . The fusion genes arising from cryptic insertions are not detectable via G-banded chromosome analysis [karyotype] but can nevertheless always be detected using fluorescence in situ hybridisation (FISH) and\/or qualitative reverse transcriptase PCR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 43-year-old female presented with suspected CML in 2007; however, contemporaneous gold standard laboratory investigations, G-banded chromosome analysis and FISH, were both negative. The reverse transcriptase quantitative PCR (RT-qPCR) assay available at the time, which was capable of detecting the common\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      transcripts (e13a2\/e14a2), was also negative. Upon review in 2009, the newly recommended reverse transcriptase multiplex PCR (capable of detecting all\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      transcripts including the atypical ones) subsequently detected an e19a2 fusion. The patient then responded to tyrosine kinase inhibitor therapy. In contrast, FISH studies of both samples with three commercially available probes remained consistently negative.\n                    <\/jats:p>\n                    <jats:p>\n                      Retrospective whole genome sequencing, undertaken as part of the 100,000 Genomes Project, has now revealed that the patient\u2019s\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      fusion gene arose via a uniquely small insertion of 122\u00a0kb\n                      <jats:italic>ABL1<\/jats:italic>\n                      sequences into\n                      <jats:italic>BCR<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We present a patient with suspected chronic myeloid leukaemia whose genetic investigations were originally negative at the time of diagnosis despite the use of contemporaneous gold standard methods.<\/jats:p>\n                    <jats:p>\n                      This is the first report of a FISH-negative,\n                      <jats:italic>BCR::ABL1<\/jats:italic>\n                      positive CML which demonstrates that, even after sixty years of research into one of the most well understood human malignancies, whole genome sequencing can yield novel diagnostic findings in CML.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-023-01607-7","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:02:23Z","timestamp":1690344143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions"],"prefix":"10.1186","volume":"16","author":[{"given":"Philippa C.","family":"May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair G.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshid S.","family":"Khorashad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Claudiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Genomics England Research Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenella","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0918-8882","authenticated-orcid":false,"given":"Andrew J.","family":"Innes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"1607_CR1","unstructured":"Nowell PC, Hungerford. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497\u2013501."},{"issue":"5405","key":"1607_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290\u20133.","journal-title":"Nature"},{"issue":"1","key":"1607_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93\u20139.","journal-title":"Cell"},{"issue":"6","key":"1607_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood.V68.6.1369.1369","volume":"68","author":"A Deklein","year":"1986","unstructured":"Deklein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F, et al. BCR rearrangement and translocation of the C-ABL Oncogene in Philadelphia positive acute lymphoblastic-leukemia. Blood. 1986;68(6):1369\u201375.","journal-title":"Blood"},{"issue":"7","key":"1607_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM197902153000702","volume":"300","author":"A Fefer","year":"1979","unstructured":"Fefer A, Cheever MA, Thomas ED, Boyd C, Ramberg R, Glucksberg H, et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med. 1979;300(7):333\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"1607_CR6","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NCP, Mueller MC, Hochhaus A, Kim DW, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330\u20138.","journal-title":"Blood"},{"issue":"22","key":"1607_CR7","doi-asserted-by":"publisher","first-page":"E111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL, et al. Establishment of the first world health organization international genetic reference panel for quantitation of BCR-ABL mRNA. Blood. 2010;116(22):E111\u20137.","journal-title":"Blood"},{"key":"1607_CR8","doi-asserted-by":"crossref","unstructured":"Druker BJ, Ohno S, Buchdunger E, Tamura S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561\u20136.","DOI":"10.1038\/nm0596-561"},{"issue":"6146","key":"1607_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/330386a0","volume":"330","author":"E Fainstein","year":"1987","unstructured":"Fainstein E, Marcelle C, Rosner A, Canaani E, Gale R, Dreazen O, et al. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature. 1987;330(6146):386\u20138.","journal-title":"Nature"},{"issue":"1","key":"1607_CR10","first-page":"208","volume":"8","author":"JV Melo","year":"1994","unstructured":"Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia. 1994;8(1):208\u201311.","journal-title":"Leukemia"},{"key":"1607_CR11","doi-asserted-by":"crossref","unstructured":"Saglio G, Guerrasio A, Rosso C, Zaccaria A, Tassinari A, Serra A, et al. New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1990;76(9):1819\u201324.","DOI":"10.1182\/blood.V76.9.1819.bloodjournal7691819"},{"key":"1607_CR12","doi-asserted-by":"crossref","unstructured":"Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction). Blood.1996;88(7):2410\u20134.","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410"},{"issue":"4","key":"1607_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.leukres.2007.08.017","volume":"32","author":"T Burmeister","year":"2008","unstructured":"Burmeister T, Reinhardt R. A multiplex PCR for improved detection of typical and atypical BCR\u2013ABL fusion transcripts. Leuk Res. 2008;32(4):579\u201385.","journal-title":"Leuk Res"},{"issue":"4","key":"1607_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/gcc.2870080406","volume":"8","author":"A Hagemeijer","year":"1993","unstructured":"Hagemeijer A, Buijs A, Smit E, Janssen B, Creemers GJ, Plas DVD, et al. Translocation of BCR to chromosome 9: A new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia. Genes Chromosom Cancer. 1993;8(4):237\u201345.","journal-title":"Genes Chromosom Cancer"},{"issue":"18","key":"1607_CR15","doi-asserted-by":"publisher","first-page":"29906","DOI":"10.18632\/oncotarget.15369","volume":"8","author":"S Luatti","year":"2017","unstructured":"Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, Soverini S, et al. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget. 2017;8(18):29906.","journal-title":"Oncotarget"},{"issue":"12","key":"1607_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/0145-2126(95)00093-3","volume":"19","author":"M Sessarego","year":"1995","unstructured":"Sessarego M, Fugazza G, Canepa L, Bacigalupo A, Bruzzone R, Patrone F. Fluorescence in situ hybridization provides evidence for two-step rearrangement in a masked Ph chromosome formation. Leuk Res. 1995;19(12):921\u20135.","journal-title":"Leuk Res"},{"issue":"6","key":"1607_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"key":"1607_CR18","first-page":"1","volume":"2020","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F, LeukemiaNet E, et al. recommendations for treating chronic myeloid leukemia. Leukemia. 2020;2020:1\u201319.","journal-title":"Leukemia"},{"issue":"6","key":"1607_CR19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809\u201320.","journal-title":"Blood"},{"issue":"2","key":"1607_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.cancergencyto.2010.08.026","volume":"203","author":"MJ Kim","year":"2010","unstructured":"Kim MJ, Cho SY, Kim M-H, Lee JJ, Kang SY, Cho EH, et al. FISH-negative cryptic PML\u2013RARA rearrangement detected by long-distance polymerase chain reaction and sequencing analyses: a case study and review of the literature. Cancer Genet Cytogenet. 2010;203(2):278\u201383.","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"1607_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1755-8166-1-14","volume":"1","author":"A Virgili","year":"2008","unstructured":"Virgili A, Brazma D, Reid AG, Howard-Reeves J, Valga\u00f1\u00f3n M, Chanalaris A, et al. FISH mapping of Philadelphia negative BCR\/ABL1 positive CML. Mol Cytogenet. 2008;1(1):14.","journal-title":"Mol Cytogenet"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01607-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:03:04Z","timestamp":1690344184000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01607-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1607"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01607-7","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"2 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All 100,000 Genome Project participants give consent to Genomics England Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient has provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PCM, AGR, MER, JSK, SC, AGR, AJI: none.DM: Honoraria from Incyte, BMS, Novartis and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"172"}}